C ase presentation: A 34-year-old woman was admitted for chest pain lasting 5 hours. She had been in excellent health except for migraine attacks with rare aura that kept her away from work about twice a month. She took no medication except for birth control pills. The ECG was unrevealing, but cardiac biomarkers were elevated. Emergency cardiac catheterization showed an occluded small left circumflex coronary artery ( Figure 1 ) and a corresponding small akinetic area in the left ventriculogram. No attempt at coronary recanalization was made because the symptoms had abated, the injured myocardium was akinetic, and there were no collaterals. However, a catheter was introduced into the right atrium, and contrast medium injection proved the suspected patent foramen ovale (PFO; Figure 2 and Movies I and II in the online-only Data Supplement). An Amplatzer PFO occluder was implanted in Ͻ10 minutes. The patient was discharged 36 hours later after her cardiac biomarkers had normalized.
Several lessons are to be gleaned from this case: (1) paradoxical embolism does not necessarily require clinically apparent deep vein thrombosis;
(2) paradoxical embolism is not confined to the brain; (3) if coronary artery disease had been present, the connection to paradoxical embolism would probably have been missed; (4) attention was correctly directed primarily at the PFO with a potential to obviate subsequent infarctions of brain, heart, or other sensitive organs; (5) echocardiography is not mandatory to prove a PFO or to close it; (6) migraine symptoms may be linked to the PFO and influenced by PFO closure; and (7) someday, workup for migraine may include screening for a PFO, and treatment for migraine may include closure of a PFO, which, in this case, would have prevented the myocardial infarction. Figure 3 and Movie III in the onlineonly Data Supplement show a large clot caught in the act of slipping through the PFO, proving the potential of a PFO to cause harm. However, the formation of such a large thrombus that will find its way to and through the PFO is an exquisite rarity. Such a problem can also be demonstrated with magnetic resonance (which is not true for the PFO itself) or computed tomography. 1 The PFO accounts for Ϸ95% of right-to-left shunts. 2 The remainder are mainly pulmonary arteriovenous fistulas (Ϸ4%) or atrial septal defects (Ϸ1%). The prevalence of a PFO ranges from 15% to 25% in autopsy studies, 3, 4 7% to 24% with transthoracic echocardiography, 5, 6 and 20% to 40% with transesophageal echocardiography in patients with a history of cerebral events. 7, 8 Tiny emboli (a few millimeters in size) that can form anywhere in the venous system are the culprits. Such emboli are absent in children and young adults with few exceptions but tend to occur with increasing frequency with age, particularly after 50 years of age. 9 Most 
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thrombi will emerge from the inferior vena cava. Both an atrial septal aneurysm (ASA), which is a flagellate central part of the septum primum forming the lower rim of the foramen ovale, and a Eustachian valve, which is a ledge extending the vena cava onto the foramen ovale, increase the chance for such clots to hit the foramen ovale and pass through it should it be open. Incessant motion in the case of the ASA and the continuous blood pounding the foramen in the case of the Eustachian valve render the fusion of the septum primum and septum secundum after birth all but impossible. The ASA and Eustachian valve increase the duration of time the flap-like PFO is actually gaping. In the case of the ASA, this may occur with every heartbeat.
It is assumed that one or both of these features are present in 2% to 4% of the population. These individuals may account for most of the mishaps attributable to the PFO, a feature present in 20% to 30% of the general population. Screening for such ominous PFO combinations (with ASA and/or Eustachian valve) may therefore make sense. 10 Yet, current guidelines of regulatory bodies concentrate on conservative therapeutic options ( Table 1) . [11] [12] [13] [14] The ASA has been a regularly cited cause for cerebral ischemic stroke. Re-ally at fault, however, is the PFO that typically went undetected in the early transthoracic echocardiograms showing only the ASA in patients with cryptogenic stroke. Most analyses corroborate the PFO as a stroke risk, at least for cryptogenic stroke. A number of studies appeared to prove the ominous role of a PFO without acknowledging it. In a 20-year population-based cohort study in Denmark 15 of almost 200 000 people, an increase in risk of myocardial infarction or stroke was recorded immediately after a clinically apparent venous thromboembolic event. The risk decreased over the subsequent year but never quite normalized.
The true peril of the PFO emerges from a study already a decade old. 16 In patients with clinically apparent pulmonary embolism, the mere presence of a PFO increased mortality from 14% to 33% and systemic embolism from 2% to 28% (PϽ0.02).
Percutaneous Closure of the PFO and the Alternatives
The first percutaneous atrial shunt closures 17 happened in the seventies, a couple of years before the first percutaneous coronary angioplasty. 18 Interest in the topic ignited, however, with a series of percutaneous PFO closures published in 1992. 19 It is estimated that Ͼ200 000 PFOs have been closed percutaneously since, with more than a dozen device designs. Success rates, defined as no significant residual shunt at the latest follow-up echocardiography, vary between 50% and 100%. 20 Randomized controlled trials comparing devices are scarce.
Complications include cardiac perforation or air embolization during implantation, induced atrial fibrillation, nonspe- cific malaise attributed to nickel allergy, and puncture site problems. Puncture site problems were the only significant complications in the past 1000 cases at our center and occurred in Ͻ1%. Thrombosis on the device during follow-up varies significantly between device families. A German registry found no thrombus with transesophageal echocardiography at 4 weeks on 292 Amplatzer occluders (AGA Medical, Plymouth, Minn), 1 (1%) on 161 Helex occluders (WL Gore and Associates, Newark, Del), 3 (7%) on 127 PFO Star occluders (Cardia Inc., Burnsville, Minn), and 7 (7%) on 100 Cardi-oSEAL/STARFlex occluders (NMT Medical, Boston, Mass). 21
PFO Closure Techniques
Percutaneous Closure
The simplest technique described so far includes the Amplatzer PFO oc-cluder. It takes Ͻ15 minutes in the catheterization laboratory, with the option of the patient pressing a finger on the venous puncture at the groin, walking out of the catheterization laboratory, leaving the hospital within a couple of hours, and participating in whatever physical activity is desired (including sports) the same day. This technique has been validated in a large consecutive patients series 22 and may prevent the problems listed in Table 2 .
So far, no noninvasive technique has been able to induce PFO closure. Local radiofrequency application (deviceless but still invasive) may someday offer an attractive option. Percutaneous intracardiac suture techniques are also in clinical evaluation. However, the PFO typically is a slit of about 20 mm requiring several well-placed stitches, an intricate task for a percutaneous approach.
Guidance with transesophageal or intracardiac echocardiography is still preferred by a majority of operators, but it has disadvantages (Table 3) . Randomized trials of PFO device closure to prevent paradoxical embolism are listed in Table 4 . 23 None has been published yet.
Surgical Closure
Although surgical closure is still mentioned as an alternative, it has all but lost its indication as an isolated procedure. None of our 1500 patients admitted for PFO closure over the past 12 years has required a surgical intervention for the PFO. However, during cardiac surgery for another reason, surgical PFO closure remains the technique of choice.
Medical Treatment
Warfarin is a better anticoagulant in the venous circulation than acetylsalicylic acid (Figure 4 ). 24, 25 Because the absolute risk for paradoxical embolism increases with age and spontaneous closure of the PFO is unlikely, medical treatment should be lifelong. In light of the superiority of oral anticoagulation, device closure of the PFO has to be compared with lifelong warfarin rather than antiplatelet treatment.
The Migraine Saga
No randomized trial has yet unequivocally shown the benefit of PFO closure for reducing the frequency of migraine headache (Table 5 ), but the accumulated clinical evidence is hard to ignore ( Figure 5 ).
Conclusions
Seeking a PFO should be part of the workup for stroke, and the term cryptogenic should be pushed beyond the exclusion of a PFO. This would result in the new stroke classification drafted in Table 6 .
Follow-Up of Case Vignette
The patient was placed on aspirin for 6 months, at which time a transesopha- geal echocardiography showed complete closure of the PFO. Therefore, aspirin was discontinued. She switched from birth control pills to an intrauterine device. In the 7 years since, she had noted a marked reduction in headache days and complete abolition of aura.
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